A 6-month claims study of 22,512 US adults who initiated tirzepatide for obesity or overweight found 68% persistence and 55% adherence using an 80% proportion-of-days-covered threshold. Persistent users with available measurements lost a mean 10.5% of body weight, and GLP-1-naïve persistent users…
A 6-month real-world study of 22,512 US adults with obesity or overweight who initiated tirzepatide found that 68% of patients remained persistent on therapy and 55% met the standard adherence threshold, with persistent users achieving a mean body weight reduction of 10.5%. The retrospective cohort analysis used the Healthcare Integrated Research Database HIRD , which links administrative claims and electronic health records, and was published in Diabetes, Obesity & Metabolism. It is one of the largest published assessments of how tirzepatide performs for weight management in routine US clinical practice rather than in a controlled trial.
The population was commercially insured adults without type 2 diabetes, mean age 46 years, 73% female. Baseline comorbidity was heavy: 91% of initiators, 20,554 people, already had at least one obesity-related complication, most frequently dyslipidaemia, hypertension, and anxiety. That profile distinguishes this cohort from tightly selected trial populations, and it matters for interpreting both the persistence numbers and the weight outcomes.
Tirzepatide is approved in the US for type 2 diabetes, weight loss, and obstructive sleep apnoea. By excluding type 2 diabetes, the investigators isolated the weight-management indication and separated the drug's glucose-lowering action from its weight effects. The report also delivered a distinct subgroup estimate: among GLP-1-naïve persistent users with available measurements, mean body weight reduction was 12.0%.
Adherence and persistence are related but distinct measures, and the study reported both over the same 6-month follow-up period. Adherence was defined by proportion of days covered PDC , the standard pharmacy metric that expresses how many days a patient had medication supply on hand as a share of the observation period. The threshold was 80%, the conventional cut-off in US quality measurement. By that definition, 55% of initiators, 12,292 people, were adherent.
Persistence was defined as continuing therapy through the 6-month follow-up. 68% of initiators, 15,208 people, were persistent. The distinction between the two measures is not a contradiction. A patient can remain on therapy for the full 6 months and still fall below an 80% PDC if gaps accumulate between refills, while a patient counted as non-persistent necessarily fails the adherence measure as well. The study captures two different failure modes: 45% of initiators fell below the adherence threshold, and 32% did not persist.
Weight outcomes were analyzed among persistent users with pre- and post-index measurements available, a subset of 808 individuals. Mean body weight reduction in that group was 10.5%. In the GLP-1-naïve subgroup the mean reduction was 12.0%, a difference consistent with patients who switch from another incretin-based drug having less weight to lose by the time they start tirzepatide. The study also assessed change in BMI and in cardiometabolic risk factors; persistent users showed numerical reductions in most of those factors. All analyses were descriptive, with no inferential statistics or adjustments, so the reductions were not tested for statistical significance.
The study was a retrospective observational cohort analysis of administrative claims and electronic health records from HIRD. Inclusion required at least one prescription claim for tirzepatide and continuous enrollment for at least 12 months before the index date and at least 6 months after it. The window for identifying initiation claims ran from November 2023 through June 2024, a period that follows the expansion of tirzepatide into the weight-management market. The index date was the date of the first tirzepatide claim, and follow-up ran 6 months.
The endpoints were adherence, persistence, change in body weight, change in BMI, and change in cardiometabolic risk factors. The design's strengths are its scale, its grounding in actual dispensing and encounter data, and its restriction to adults without type 2 diabetes, which makes the weight estimates specific to the weight-management indication. The separate GLP-1-naïve analysis adds specificity that most comparable real-world studies have not reported.
What the design cannot do is establish causation. There is no control group, no randomization, and no adjustment for confounders, and the weight estimate rests on 808 persistent individuals, a subgroup of the 15,208 persistent patients and a small fraction of the 22,512 initiators. Patients who remained engaged enough to have weights recorded in the data may differ from those who were not, in adherence behavior, follow-up intensity, or both. Claims data also do not record why patients stopped therapy. The findings describe what happens among patients who stay on tirzepatide in this commercially insured population; they do not estimate the drug's effect across all initiators.
Tirzepatide is a peptide-based dual agonist: a single synthetic peptide engineered to activate both the GIP receptor and the GLP-1 receptor, two class B G protein-coupled receptors. GLP-1 receptor activation drives glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system signaling. Because insulin secretion is tied to ambient glucose, the incretin mechanism carries a low intrinsic risk of hypoglycaemia, which is one reason these drugs can be used for weight management without routine glucose monitoring.
GIP was long treated as a minor incretin, but GIP receptors are expressed in the brain, including hypothalamic appetite circuits, and in adipose tissue. Evidence accumulated over the past two decades indicates that GIP signaling contributes to satiety and energy storage, and that coordinated GIP and GLP-1 agonism produces greater weight reduction than GLP-1 agonism alone. The molecular details are still an active research area, but the clinical consequence is that tirzepatide's weight effect depends on the continuous presence of the peptide at both receptors.
That pharmacology is directly relevant to a persistence study. Tirzepatide is given as a once-weekly subcutaneous injection, and weight loss develops over weeks and months rather than days. A missed dose, a delayed refill, or a stop weakens the anorectic signal before the body has adapted to the lower weight. Adherence and persistence are therefore not administrative footnotes; they are proximate determinants of whether the drug's mechanism is given the chance to produce its clinical effect. The observed 68% persistence over 6 months describes how often that happened in routine US practice.
Peptide Atlas's registry currently lists 251 registered clinical trials involving tirzepatide, 10 of them recruiting. The phase designations on file are one Phase 3 trial, five Phase 2 trials, and two Phase 4 trials. The registered program shows the drug moving beyond its original metabolic indications into cardiovascular, neurobehavioral, and musculoskeletal questions.
The muscle trial is notable because rapid weight loss raises a direct question about what fraction of lost weight is lean mass, and the trial's stated focus is muscle morphology, quality, and physical function in a population that, like the HIRD cohort, is overweight or obese without type 2 diabetes. The two atrial fibrillation trials point toward structural cardiac endpoints, and the cannabis use disorder trial signals neurobehavioral expansion.
The indexed literature on file at Peptide Atlas includes 188 PubMed papers on tirzepatide, and the recent strata show the same real-world turn as the HIRD study. PMID 42383938, published in Mayo Clinic Proceedings on 2026-06-30, is a multicentered real-world comparative effectiveness study of tirzepatide and semaglutide for obesity. PMID 42397506, in Hepatology International on 2026-07-03, compared tirzepatide with SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease using propensity matching across multiple centers. PMID 42387290, in Diabetes, Obesity & Metabolism on 2026-07-01, reported improved metabolic outcomes with tirzepatide in type 1 diabetes with overweight or obesity. PMID 42387035, in Endocrine on 2026-07-01, reviewed the molecular mechanisms behind tirzepatide's multi-organ effects. PMID 42381258, in the American Journal of Case Reports on 2026-07-01, documented starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use in a non-obese, non-diabetic woman. The HIRD study adds adherence, persistence, and weight data from a large US claims population to a literature increasingly built on real-world sources.
For clinicians, the study supplies planning numbers. About two of three patients who start tirzepatide for weight management will still be on it at 6 months, and about one in two will meet the 80% PDC benchmark. Among patients who persist and have weight recorded, the mean loss exceeds the 5% threshold that defines clinically meaningful weight loss in obesity medicine. The estimate among GLP-1-naïve users gives a more relevant expectation for the patient beginning tirzepatide as a first incretin-based therapy.
For researchers, the report is both a benchmark and a caution. Real-world adherence and effectiveness data for tirzepatide specifically, in a population without type 2 diabetes, are scarce, so the cohort provides reference points for later work. The caution is methodological: of 15,208 persistent patients, only 808 had pre- and post-index weight measurements, a reminder of how quickly a large claims population can shrink into a small analyzed sample. Future studies should treat weight and laboratory measurement as outcomes to be collected systematically, and should include comparator arms and adjusted analyses.
For the peptide supply chain, the persistence data carry a planning implication: demand for tirzepatide concentrates among persistent users, because continuous once-weekly exposure is what produces the observed results. Forecasts built on initiation volumes will overstate duration of use if one third of initiators stop within 6 months. The market in compounded and research-grade tirzepatide makes quality verification a supply chain concern; Peptide Atlas currently holds four third-party laboratory purity test results for tirzepatide on file, with the highest observed purity at 99.864%. Combination development, including the registered Phase 2 trial of NA-931 plus tirzepatide, will reshape future demand.
For payers and formulary committees, persistence and adherence are the metrics used in value assessments and utilization management. A 68% persistence rate and a 55% adherence rate at 6 months provide a real-world baseline…
Peptides referenced: Semaglutide, Tirzepatide, Glucagon, GLP-1.
Related reading: STEP 12: Semaglutide 2.4 mg Cuts Weight in Chinese Adults by 9.9 Points, Semaglutide Slows Rise in Dementia Risk Signature in SELECT Analysis, Why Weight Returns After GLP-1 Agonist Therapy Is Stopped, UK first in Europe to approve Eli Lilly oral GLP-1 orforglipron.